SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction: Transforming Melanoma Risk Assessment

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), April 4, 2025—SkylineDx, an innovative diagnostics company specializing in molecular diagnostics for oncology, inflammatory, and infectious diseases, proudly announces that Dr. Teresa Amaral MD, PhD,...

SkylineDx Presents Landmark Findings from the Largest Prospective Multicenter Melanoma GEP trial at SSO 2025

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 28, 2025—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology , inflammatory and infectious diseases, proudly announces...

SkylineDx Announces New Study Demonstrating Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Advanced Merlin CP-GEP test

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 12, 2025—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces...

SkylineDx Announces New Publication On SKY92 Gene Expression Profiling Test in Defining Ultra-High-Risk Multiple Myeloma

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), February 28, 2025—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces the...

New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 7, 2024—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announce that groundbreaking...

Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 25, 2024—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today the...

SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene Expression Profiling Trial at 21st International Congress of the Society for Melanoma Research

The Merlin test (CP-GEP) stratifies melanoma patients based on risk for sentinel lymph node (SLN) metastasis, offering a powerful tool for risk-based decision-making. ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 13,...

SkylineDx Announces Presentation of New Data Highlighting the Predictive Power of the CP-GEP Merlin Test for T1a Cutaneous Melanoma Patients at the 21st International Congress of the Society for Melanoma Research

The Merlin Test  (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October...

SkylineDx Announces Upcoming Oral Presentation at the 21st International Congress of the Society for Melanoma Research

ROTTERDAM, (the Netherlands), SAN DIEGO (CA, USA), October 8, 2024 – SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announces...

SkylineDx Announces All Patients Enrolled in Landmark Study MERLIN_001, Advancing Melanoma Diagnostics

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), July 9, 2024: — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, proudly...

SkylineDx’s Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB for recurrence

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 30, 2024: — SkylineDx announces the presentation of groundbreaking data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Dr. Teresa Amaral,...

Independent European data on CP-GEP model in Stratifying Melanoma Patients for Long Term Survival

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), April 5, 2024: — SkylineDx is pleased to announce two forthcoming scientific publications at the European Association for Dermato-Oncology congress, April 4-6, 2024. These publications...

Independent validation of performance Merlin Test in Swedish patients

ROTTERDAM (the Netherlands), SAN DIEGO (USA), March 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients was independently validated in a Swedish (European) cohort, where it could reduce approximately a...

SkylineDx Launches New Global Corporate Website

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 20, 2024: – SkylineDx, an innovative molecular diagnostics company, proudly announces the launch of its new corporate website, a testament to the company’s commitment...

Melanoma risk prediction of nodal metastasis and long-term survival outcome by CP-GEP model in a U.S. cohort

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 8, 2024: — SkylineDx, an innovative molecular diagnostics company, announces the forthcoming presentation of an impactful poster by Dr. Yu from University Hospital Cleveland...

SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis and Treatment

ROTTERDAM, the Netherlands, SAN DIEGO, CA, USA – January 9, 2024: SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European...

SkylineDx and VIB Initiate Joint Research Program on Immune Prediction

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 11, 2023: — SkylineDx, an innovative molecular diagnostics company, is thrilled to announce that a collaborative project for precision medicine, POINTILLISM 2.0, has been selected...

SkylineDx Presents Pioneering Data at ASH 2023: SKY92 Risk Stratification in Multiple Myeloma Patients

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 8th 2023: –  SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics is looking forward to the release of new data...